Mostrar el registro sencillo del ítem

dc.contributor.authorIglesies-Grau, Josep
dc.contributor.authorGarcia-Alvarez, Ana 
dc.contributor.authorOliva, Belen 
dc.contributor.authorMendieta, Guiomar
dc.contributor.authorGarcia-Lunar, Ines 
dc.contributor.authorFuster, Jose J. 
dc.contributor.authorDevesa, Ana
dc.contributor.authorPérez-Herreras, Cristina
dc.contributor.authorFernandez-Ortiz, Antonio 
dc.contributor.authorBrugada, Ramon 
dc.contributor.authorIbáñez, Borja 
dc.contributor.authorFernandez-Jimenez, Rodrigo 
dc.contributor.authorFuster, Valentin
dc.date.accessioned2024-05-09T13:59:57Z
dc.date.available2024-05-09T13:59:57Z
dc.date.issued2023-12-19
dc.identifier.citationCardiovasc Diabetol. 2023 Dec 19;22(1):350.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/19335
dc.description.abstractBACKGROUND Elevated glycated hemoglobin (HbA1c) is associated with a higher burden of subclinical atherosclerosis (SA). However, the association with SA of earlier insulin resistance markers is poorly understood. The study assessed the association between the homeostatic model assessment of insulin resistance index (HOMA-IR) and SA in addition to the effect of cardiovascular risk factors (CVRFs) in individuals with normal HbA1c. METHODS A cohort of 3,741 middle-aged individuals from the Progression of Early Subclinical Atherosclerosis (PESA) study with basal HbA1c < 6.0% (< 42 mmol/mol) and no known CV disease underwent extensive imaging (multiterritorial vascular ultrasound and coronary artery calcium score, CACS) to assess the presence, burden, and extent of SA. RESULTS Individuals with higher HOMA-IR values had higher rates of CVRFs. HOMA-IR showed a direct association with the multiterritorial extent of SA and CACS (p < 0.001) and with global plaque volume measured by 3-dimensional vascular ultrasound (p < 0.001). After adjusting for key CVRFs and HbA1c, HOMA-IR values ≥ 3 were associated with both the multiterritorial extent of SA (odds ratio 1.41; 95%CI: 1.01 to 1.95, p = 0.041) and CACS > 0 (odds ratio 1.74; 95%CI: 1.20 to 2.54, p = 0.004), as compared with the HOMA-IR < 2 (the reference HOMA-IR category). In a stratified analysis, this association remained significant in individuals with a low-to-moderate SCORE2 risk estimate (75.6% of the cohort) but not in high-risk individuals. CONCLUSIONS The use of HOMA-IR identified low-risk individuals with a higher burden of SA, after adjusting for the effects of key traditional CVRFs and HbA1c. HOMA-IR is a simple measure that could facilitate earlier implementation of primary CV prevention strategies in clinical practice.es_ES
dc.description.sponsorshipThe PESA study is co-funded by the Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain, and Banco Santander, Madrid, Spain. The study also receives funding from the Instituto de Salud Carlos III (ISCIII) (PI15/02019) and the European Regional Development Fund (ERDF) “Una manera de hacer Europa”. RF-J is the recipient of grants PI19/01704 and PI22/01560 funded by the ISCIII-Fondo de Investigación Sanitaria and co-funded by the European Union. The CNIC is supported by the ISCIII, the Ministerio de Ciencia, Innovación y Universidades, and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (grant CEX2020- 001041-S funded by MICIN/AEI/https://doi.org/10.13039/501100011033).es_ES
dc.language.isoenges_ES
dc.publisherBioMed Central (BMC) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshInsulin Resistance es_ES
dc.subject.meshAtherosclerosis es_ES
dc.subject.meshPlaque, Atherosclerotices_ES
dc.subject.meshMiddle Aged es_ES
dc.subject.meshHumans es_ES
dc.subject.meshGlycated Hemoglobines_ES
dc.subject.meshRisk Factors es_ES
dc.titleEarly insulin resistance in normoglycemic low-risk individuals is associated with subclinical atherosclerosis.es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID38115031es_ES
dc.format.volume22es_ES
dc.format.number1es_ES
dc.format.page350es_ES
dc.identifier.doi10.1186/s12933-023-02090-1es_ES
dc.contributor.funderCentro Nacional de Investigaciones Cardiovasculares Carlos III (España) es_ES
dc.contributor.funderBanco Santander es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) es_ES
dc.contributor.funderFundación ProCNIC es_ES
dc.contributor.funderMinisterio de Ciencia e Innovación. Centro de Excelencia Severo Ochoa (España) es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1475-2840es_ES
dc.relation.publisherversion10.1186/s12933-023-02090-1es_ES
dc.identifier.journalCardiovascular diabetologyes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Laboratorio Traslacional para la Imagen y Terapia Cardiovasculares_ES
dc.repisalud.institucionCNICes_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional